arrow
P

Piers Patten

king's collegelondon
H指数:34
被引数:5,184

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

TLR9-dependent migration identifies different Chronic Lymphocytic Leukemia signaling states under BTK inhibition.

TLR9依赖性迁移识别BTK抑制下慢性淋巴细胞白血病的不同信号状态。

Blood
IF23.1
2026-10-070
OAAI
Acalabrutinib monotherapy as a first-line treatment for CLL: 3 years follow-up of the real-world EPIC study

阿卡巴鲁替尼单药治疗作为CLL的一线治疗:真实世界EPIC研究的3年随访

2026-05-020
OAAI
Final phase 2 study results of acalabrutinib in treatment-naive and relapsed/refractory chronic lymphocytic leukemia

Acalabrutinib在初治及复发/难治性慢性淋巴细胞白血病中的最终II期研究结果

2026-04-020
OAAI
Patient-reported health-related quality of life in previously untreated chronic lymphocytic leukaemia: Results from the randomised phase 3 FLAIR trial comparing ibrutinib-rituximab versus fludarabine-cyclophosphamide-rituximab

既往未治疗的慢性淋巴细胞白血病患者报告的健康相关生活质量:来自比较伊布替尼-利妥昔单抗与氟达拉滨-环磷酰胺-利妥昔单抗的随机III期FLAIR试验的结果

2026-03-010
OAAI
Final analysis of the RESONATE-2 study: up to 10 years of follow-up of first-line ibrutinib treatment for CLL/SLL

RESONATE-2研究的最终分析:ibrutinib作为CLL/SLL患者一线治疗长达10年的随访研究

Blood
IF23.1
2025-08-050
OAAI
Transposable elements as novel therapeutic targets for PARPi-induced synthetic lethality in PcG mutated blood cancer

转座元件作为PARPi诱导的PcG突变血液肿瘤中合成致死性的新型治疗靶点

Blood
IF23.1
2025-07-080
OA
Outcomes after chimeric antigen receptor T-cell therapy across large B-cell lymphoma subtypes
2024-04-040
OAAI
Chronic Lymphocytic Leukemia Therapy Guided by Measurable Residual Disease

以可测量的残留疾病为指导的慢性淋巴细胞白血病治疗

2024-01-2550
OA
Efficacy comparison of tisagenlecleucel vs usual care in patients with relapsed or refractory follicular lymphoma
2022-11-2225
OAAI